1-(4’-溴苯氧基)-1-乙氧基乙烷 | 39255-20-4

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(4’-溴苯氧基)-1-乙氧基乙烷
• 中文别名: 1-(4'-溴苯氧基)-1-乙氧基乙烷；1-(4`-溴苯氧基)-1-乙氧基乙烷
• 英文名称: 1-bromo-4-[2-(ethoxy)ethoxy]benzene
• 英文别名: 1-bromo-4-(2-ethoxyethoxy)benzene
• CAS: 39255-20-4
• 化学式: C₁₀H₁₃BrO₂
• mdl: MFCD11878628
• 分子量: 245.116
• InChiKey: QACZJJNHOATNHA-UHFFFAOYSA-N

物化性质

• 沸点：
  130-132 °C
• 密度：
  1.4154 (rough estimate)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37
• 海关编码：
  2909309090

SDS

Name:	1-(4'-Bromophenoxy)-1-Ethoxyethane Material Safety Data Sheet
Synonym:	None known.
CAS:	39255-20-4

Section 1 - Chemical Product MSDS Name: 1-(4'-Bromophenoxy)-1-Ethoxyethane Material Safety Data Sheet
Synonym: None known.

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
39255-20-4	1-(4'-Bromophenoxy)-1-Ethoxyethane	ca 100	254-383-6

Hazard Symbols: XI
Risk Phrases: 36/37

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Irritating to eyes and respiratory system.The toxicological properties of this material have not been fully investigated. Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
May cause skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 39255-20-4: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Clear liquid
Color: green-yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 130.0 - 132.0 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H13BrO2
Molecular Weight: 245.12

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen bromide, bromine fumes.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 39255-20-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-(4'-Bromophenoxy)-1-Ethoxyethane - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37 Irritating to eyes and respiratory system.
Safety Phrases:
S 24/25 Avoid contact with skin and eyes. S 28A After contact with skin, wash immediately with plenty of water. S 37 Wear suitable gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 39255-20-4: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 39255-20-4 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 39255-20-4 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 4/05/1997 Revision #7 Date: 3/04/2004 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4’-溴苯氧基)-1-乙氧基乙烷 在 四(三苯基膦)钯 、 氯化亚砜 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 生成 C₁₂H₁₈ClO₄P
  参考文献：
  名称：

  New Type of Metalloproteinase Inhibitor:  Design and Synthesis of New Phosphonamide-Based Hydroxamic Acids

  摘要：

  A series of phosphonamide-based hydroxamate derivatives were synthesized, and the inhibitory activities were evaluated against various metalloproteinases in order to clarify its selectivity profile. Among the four diastereomeric isomers resulting from the chirality at the C-3 and P atoms, the compound with a (R,R)-configuration both at the C-3 position and the phosphorus atom was found to be potently active, while the other diastereomeric isomers were almost inactive. A number of (R,R)-compounds synthesized here exhibited broad spectrum activities with nanomolar K-i values against MMP-1, -3, -9, and TACE and also showed nanomolar IC50 values against HB-EGF shedding in a cell-based inhibition assay. The modeling study using X-ray structure of MMP-3 suggested the possible binding mode of the phosphonamide-based inhibitors.

  DOI：

  10.1021/jm0103211
• 作为产物：
  描述：

  4-溴苯酚 、 2-溴乙基乙基醚 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 18.0h， 以86%的产率得到1-(4’-溴苯氧基)-1-乙氧基乙烷
  参考文献：
  名称：

  [EN] ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS
  [FR] DERIVES AMIDE ET ACIDE ARYLSULFONYLHYDROXAMIQUE, UTILISATION DE CES DERNIERS EN TANT QU'INHIBITEURS DE PROTEASES

  摘要：

  这项发明通常涉及羟肟酸和酰胺化合物（包括这些化合物的盐），更具体地涉及芳基和杂环芳基磺酰甲基羟肟酸和酰胺，这些化合物在某些情况下抑制蛋白酶活性，特别是基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性。这些化合物通常在结构上对应于式（I）：其中Al、A2、A3、El、E2、E3和E4如本专利中所定义。这项发明还涉及这些化合物的组合物、合成这些化合物的中间体、制备这些化合物的方法，以及治疗与MMP活性和/或聚集素酶活性相关的病症的方法。

  公开号：

  WO2004000811A1

文献信息

• Optically active compound and photosensitive resin composition
  申请人：——

  公开号：US20030211421A1

  公开（公告）日：2003-11-13

  A photoactive compound is used in combination with a photosensitizer, represented by the following formula (1): A −[( J ) m −( X-Pro )] n (1) wherein A represents a hydrophobic unit comprising at least one kind of hydrophobic groups selected from a hydrocarbon group and a heterocyclic group, J represents a connecting group, X-Pro represents a hydrophilic group protected by a protective group Pro which is removable by light exposure, m represents 0 or 1, and n represents an integer of not less than 1. The protective group Pro may be removable by light exposure in association with the photosensitizer (especially, a photo acid generator), or may be a hydrophobic protective group. The hydrophilic group may be a hydroxyl group or a carboxyl group. The photoactive compound has high sensitivity to a light source of short wavelength beams, for resist application, therefore, the photoactive compound is advantageously used for forming a pattern with high resolution.

  一种光活性化合物与光敏剂结合使用，由以下公式（1）表示： A −[( J ) m −( X-Pro )] n (1) 其中，A代表至少包括一种从烃基和杂环基中选择的疏水基的疏水单元，J代表连接基团，X-Pro代表由光照可去除的保护基团Pro保护的亲水基团，m代表0或1，n代表不少于1的整数。 保护基团Pro可以与光敏剂（特别是光酸发生剂）一起通过光照可去除，也可以是疏水保护基团。亲水基团可以是羟基或羧基。光活性化合物对短波长光源具有很高的敏感性，用于光刻应用，因此，该光活性化合物有利于形成具有高分辨率的图案。
• Anilide derivative, production and use thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06235771B1

  公开（公告）日：2001-05-22

  This invention is to provide a compound of the formula: wherein R1 is an optionally substituted 5- to 6-membered ring; the ring A is an optionally substituted 6- to 7-membered ring; the ring B is an optionally substituted benzene ring; n is an integer of 1 or 2; Z is a chemical bond or a divalent group; R2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, (2) an optionally substituted nitrogen-containing heterocyclic ring group which may contain a sulfur atom or an oxygen atom as ring constituting atoms and wherein a nitrogen atom may form a quaternary ammonium, (3) a group binding through a sulfur atom or (4) a group of the formula:  wherein k is 0 or 1, and when k is 0, a phosphorus atom may form a phosphonium; and R5 and R6 are independently an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted amino group, and R5 and R6 may bind to each other to form a cyclic group together with the adjacent phosphorus atom, or a salt thereof , which is useful for antagonizing CCR5 and also for the prevention and treatment of infectious disease of HIV.

  这项发明提供了以下式的化合物： 其中R1是一个可选择取代的5至6成员环；环A是一个可选择取代的6至7成员环；环B是一个可选择取代的苯环；n是1或2的整数；Z是化学键或二价基团；R2是(1)一个可选择取代的氨基团，其中氮原子可以形成季铵盐，(2)一个可选择取代的含氮杂环环基团，可能含有硫原子或氧原子作为环构成原子，其中氮原子可以形成季铵盐，(3)通过硫原子结合的基团或(4)下式的基团： 其中k为0或1，当k为0时，磷原子可以形成磷铵盐；R5和R6分别是可选择取代的碳氢基团、可选择取代的羟基或可选择取代的氨基团，R5和R6可以结合在一起与相邻的磷原子形成环状基团，或其盐，用于拮抗CCR5并用于预防和治疗HIV感染疾病。
• Orally Active CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Activity of 1-Benzothiepine 1,1-Dioxide and 1-Benzazepine Derivatives Containing a Tertiary Amine Moiety
  作者：Masaki Seto、Yoshio Aramaki、Tomohiro Okawa、Naoki Miyamoto、Katsuji Aikawa、Naoyuki Kanzaki、Shin-ichi Niwa、Yuji Iizawa、Masanori Baba、Mitsuru Shiraishi

  DOI：10.1248/cpb.52.577

  日期：——

  (hetero)arylmethyl groups as the 1-substituent on the 1-benzazepine ring together with the 2-(butoxy)ethoxy group led to further increase of activity. Among the 1-benzazepine derivatives, the isobutyl (6i), benzyl (6o) or 1-methylpyrazol-4-ylmethyl (6s) compounds were found to exhibit highly potent inhibitory effects, equivalent to the injectable CCR5 antagonist 1, in the HIV-1 envelope-mediated membrane fusion

  通过化学修饰含有叔胺部分的1-苯并噻庚因1,1-二氧化物3和1-苯并ze庚因4铅化合物来进行口服活性CCR5拮抗剂的研究。在1-苯并噻吩环的7-苯基上的4-位用2-（C（2-4）烷氧基）乙氧基取代甲基导致口服时活性增强和药代动力学特性显着改善大鼠给药。引入C（2-4）烷基，苯基或（杂）芳基甲基作为1-苯并ze庚因环上的1-取代基与2-（丁氧基）乙氧基一起导致活性的进一步提高。在1-苯并ze庚因衍生物中，发现异丁基（6i），苄基（6o）或1-甲基吡唑-4-基甲基（6s）化合物具有很强的抑制作用，在HIV-1包膜介导的膜融合测定中，其等同于可注射的CCR5拮抗剂1。特别是，化合物6s对膜融合表现出最强的CCR5拮抗活性（IC（50）= 2.7 nM）和抑制作用（IC（50）= 1.2 nM），并且在大鼠中具有良好的药代动力学特性。描述了1-苯并噻庚因1，1-二氧化物和1-苯并ze庚因衍生物的合成及其生物学活性。
• Hydroxamic acid and amide compounds and their use as protease inhibitors
  申请人：——

  公开号：US20040167182A1

  公开（公告）日：2004-08-26

  This invention is directed generally to hydroxamic acid and amide compounds (including salts of such compounds), and, more particularly, to aryl- and heteroaryl-arylsulfonylmethyl hydroxamic acids and amides that, inter alia, inhibit protease activity, particularly matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. These compounds generally correspond in structure to Formula I: 1 wherein A 1 , A 2 , A 3 , E 1 , E 2 , E 3 , and E 4 are as defined in this patent. This invention also is directed to compositions of such compounds, intermediates for the syntheses of such compounds, methods for making such compounds, and methods for treating conditions associated with MMP activity and/or aggrecanase activity, particularly pathological conditions.

  本发明通常涉及羟肟酸和酰胺化合物（包括这些化合物的盐），更具体地涉及芳基和杂环芳基磺酰甲基羟肟酸和酰胺，这些化合物在抑制蛋白酶活性，特别是基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性方面具有作用。这些化合物通常与公式I相对应：其中A1，A2，A3，E1，E2，E3和E4如本专利所定义。本发明还涉及这些化合物的组合物，合成这些化合物的中间体，制备这些化合物的方法以及治疗与MMP活性和/或聚集素酶活性相关的病理性状的方法。
• Aminophenylpropanoic Acid Derivative
  申请人：Yasuma Tsuneo

  公开号：US20080269220A1

  公开（公告）日：2008-10-30

  A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.

  化合物的化学式为（1）：其中每个符号如规范所定义，其盐和前药意外地具有更优越的GPR40受体激动剂活性，在药品产品的稳定性等方面具有优越性，并且可以作为安全有效的药物用于预防或治疗GPR40受体相关的病理或疾病，例如糖尿病等。